Our results not only provide molecular insights into the novel role of FMRP in tuning presynaptic inhibition, but also identify a loss of the Kv1.2–FMRP interaction as a key locus for the pathogenesis of FXS. The gene discussed is FMR1; the disease is fragile X syndrome.